Omeros Corporation is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for a range of medical conditions. The company leverages its expertise in pharmacology and drug development to create innovative treatments, particularly in the fields of inflammation, ophthalmology, and central nervous system disorders. Omeros is committed to addressing unmet medical needs through its proprietary drug candidates, which include both standalone therapies and supportive care products designed to enhance patient outcomes. With a strong emphasis on research and clinical development, Omeros aims to bring transformative therapies to market that improve the lives of patients suffering from complex diseases. Read More
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab across both the pivotal clinical trial and the global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of complement, and is currently under review for marketing approval by both the U.S. FDA and the European Medicines Agency.
Investors searching for small cap stocks under $5 are finding opportunities across biotech, AI, mining, energy, and fintech sectors. Below are several low-priced stocks to watch that combine high-growth potential with upcoming catalysts in Q4 2025.
In a dramatic turn of events that sent shockwaves through the biotechnology sector, Omeros Corporation (NASDAQ: OMER) witnessed its stock catapult by an astounding nearly 150% after announcing a colossal licensing agreement with pharmaceutical titan Novo Nordisk (CPH: NOVO B). The deal, potentially valued at up to $2.1 billion,
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab through a global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of complement, and is currently under review for marketing approval by both the U.S. FDA and the European Medicines Agency.
Omeros Corp (OMER) reports Q2 2025 with narrowed losses, progress on narsoplimab FDA approval, and strategic debt restructuring. Shares rise on regulatory optimism.
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include:
